Related Experiment Video
Updated: Jul 17, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Comprehensive bioinformatics analysis reveals key hub genes linked to prognosis in multiple myeloma with drug
Xi-Tian Chen1, Yi-Peng Wu2, Yong-Qing Li1
1Department of Hematology, Jieyang People's Hospital, Jieyang, China.
Abstract:
Multiple myeloma (MM) is an incurable hematologic malignancy, with chemotherapy being the primary treatment. However, the development of drug resistance remains a major challenge. This study aimed to identify therapeutic targets associated with drug resistance in MM and assess their prognostic significance. Gene expression data from GSE82307, GSE146649, and GSE136725 were analyzed to identify differentially expressed genes (DEGs) using the "limma" and "RobustRankAggreg" R packages. Functional enrichment analysis and protein-protein interaction (PPI) network analysis were performed, with key network modules identified using Cytoscape. The expression and prognostic relevance of DEGs were validated using MM patient samples from the GSE136725 and MMRF CoMMpass databases. A total of 4623 DEGs were identified, and robust rank aggregation analysis revealed the top 20 upregulated genes. Among them, AURKA, DLGAP5, BUB1B, and KIF20A were highly expressed in drug-resistant patients and were associated with poor prognosis. The findings suggest that AURKA, DLGAP5, BUB1B, and KIF20A are potential biomarkers linked to drug resistance and recurrence in MM. Further studies are required to elucidate the underlying molecular mechanisms and explore their potential as therapeutic targets.
Insights
This study identifies key genes, including AURKA and DLGAP5, linked to drug resistance in multiple myeloma (MM). These genes indicate poor prognosis and may serve as therapeutic targets for this incurable cancer.
Area of Science:
- Hematologic Malignancies
- Cancer Genomics
- Drug Resistance Mechanisms
Background:
- Multiple myeloma (MM) is an incurable hematologic malignancy primarily treated with chemotherapy.
- Drug resistance is a significant challenge in MM treatment, necessitating the identification of novel therapeutic targets.
Purpose of the Study:
- To identify therapeutic targets associated with drug resistance in MM.
- To assess the prognostic significance of identified therapeutic targets in MM patients.
Main Methods:
- Differential gene expression analysis of MM datasets (GSE82307, GSE146649, GSE136725) using R packages.
- Functional enrichment, protein-protein interaction (PPI) network analysis, and module identification using Cytoscape.
- Validation of gene expression and prognostic relevance in MM patient cohorts (GSE136725, MMRF CoMMpass).
Main Results:
- Identified 4623 differentially expressed genes (DEGs) between drug-sensitive and resistant MM.
- Robust rank aggregation highlighted top upregulated genes, with AURKA, DLGAP5, BUB1B, and KIF20A showing high expression in drug-resistant MM.
- These four genes were significantly associated with poor prognosis in MM patients.
Conclusions:
- AURKA, DLGAP5, BUB1B, and KIF20A are potential biomarkers for drug resistance and recurrence in multiple myeloma.
- These genes represent promising therapeutic targets for overcoming drug resistance in MM.
- Further research is warranted to explore the molecular mechanisms and therapeutic potential of these identified genes.
